SOUTH SAN FRANCISCO, Calif., Dec. 9, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to an employee's entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 187,500 stock options to Ray Furey vesting over four years with a one-year cliff. Additionally, Mr. Furey was granted 187,500 stock options to vest upon achievement of certain future performance conditions, subject to Mr. Furey's continuous service to the Company on such vesting date. 

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, visit www.rigel.com.

Rigel Contacts
Media:
David Rosen, Argot Partners
Phone: 212.600.1902
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:
Rigel Pharmaceuticals, Inc. 
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it.